Iminosugar inhibitors for treating the lysosomal glycosphingolipidoses

Iminosugar inhibitors for treating the lysosomal glycosphingolipidoses

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Butters, T, Dwek, R, Platt, F
Formato:	Conference item
Publicado:	2005

Ejemplares similares

Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses.
por: Butters, T, et al.
Publicado: (2005)

Substrate reduction therapy in mouse models of the glycosphingolipidoses.
por: Platt, F, et al.
Publicado: (2003)

Iminosugars and methods of treating Arenaviral infections
por: Ramstedt, U, et al.
Publicado: (2010)

Iminosugars and methods of treating viral diseases
por: Ramstedt, U, et al.
Publicado: (2011)

Iminosugars and methods of treating Filoviral diseases
por: Ramstedt, U, et al.
Publicado: (2011)

Iminosugars and methods of treating Bunyaviral and Togaviral diseases
por: Ramstedt, U, et al.
Publicado: (2010)

Storage solutions: treating lysosomal disorders of the brain.
por: Jeyakumar, M, et al.
Publicado: (2005)

Can P-glycoprotein influence the bioavailability of iminosugar-based glucosylceramide synthase inhibitors?
por: Norris-Cervetto, E, et al.
Publicado: (2006)

Therapeutic applications of imino sugars in lysosomal storage disorders.
por: Butters, T, et al.
Publicado: (2003)

New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases.
por: Butters, T, et al.
Publicado: (2003)

Inhibition of glycosphingolipid biosynthesis: application to lysosomal storage disorders.
por: Butters, T, et al.
Publicado: (2000)

Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.
por: Jeyakumar, M, et al.
Publicado: (2002)

Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders.
por: Butters, T, et al.
Publicado: (2003)

Design and synthesis of iminosugar-based inhibitors of glucosylceramide synthase: the search for new therapeutic agents against Gaucher disease
por: Boucheron, C, et al.
Publicado: (2005)

Iminosugar for treatment of tumors
por: Dwek, R, et al.
Publicado: (2008)

Study of the mechanism of antiviral action of iminosugar derivatives against bovine viral diarrhea virus.
por: Durantel, D, et al.
Publicado: (2001)

Lysosomal storage of oligosaccharide and glycosphingolipid in imino sugar treated cells.
por: Boomkamp, S, et al.
Publicado: (2010)

Iminosugar antivirals: the therapeutic sweet spot
por: Alonzi, D, et al.
Publicado: (2017)

Assessment of Target Engagement in a First‐in‐Human Trial with Sinbaglustat, an Iminosugar to Treat Lysosomal Storage Disorders
por: Martine Gehin, et al.
Publicado: (2021-03-01)

Use of iminosugar derivatives to inhibit ion channel activity
por: Zitzmann, N, et al.
Publicado: (2004)

Glycosphingolipid profiling of tissues from mouse models of human lysosomal storage disorders
por: Priestman, D, et al.
Publicado: (2008)

Antiviral effects of an iminosugar derivative on flavivirus infections.
por: Wu, S, et al.
Publicado: (2002)

Design and synthesis of iminosugar-based inhibitors of glucosylceramide synthase: the search for new therapeutic agents against Gaucher disease (vol 16, pg 1747, 2005)
por: Boucheron, C, et al.
Publicado: (2005)

Substrate deprivation: a new therapeutic approach for the glycosphingolipid lysosomal storage diseases.
por: Platt, F, et al.
Publicado: (2000)

N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.
por: Andersson, U, et al.
Publicado: (2000)

Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus.
por: Steinmann, E, et al.
Publicado: (2007)

New developments in treating glycosphingolipid storage diseases.
por: Platt, F, et al.
Publicado: (2005)

<i>N</i>-Alkylated Iminosugar Based Ligands: Synthesis and Inhibition of Human Lysosomal β-Glucocerebrosidase
por: Andreas Wolfsgruber, et al.
Publicado: (2020-10-01)

A Novel Iminosugar UV-12 with Activity against the Diverse Viruses Influenza and Dengue (Novel Iminosugar Antiviral for Influenza and Dengue)
por: Kelly L. Warfield, et al.
Publicado: (2015-05-01)

Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases
por: Silk, J, et al.
Publicado: (2005)

Treating lysosomal storage disorders: current practice and future prospects.
por: Platt, F, et al.
Publicado: (2009)

Long alkylchain iminosugars block the HCV p7 ion channel
por: Pavlovic, D, et al.
Publicado: (2005)

Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases.
por: Gadola, S, et al.
Publicado: (2006)

Erratum: Design and synthesis of iminosugar-based inhibitors of glucosylceramide synthase: The search for new therapeutic agents against Gaucher disease (Tetrahedron: Asymmetry (2005) 16 (1747) DOI: 10.1016/j.tetasy.2005.03. 015)
por: Boucheron, C, et al.
Publicado: (2005)

Liposome-mediated delivery of iminosugars enhances efficacy against dengue virus in vivo.
por: Miller, J, et al.
Publicado: (2012)

Isolation and SAR studies of bicyclic iminosugars from Castanospermum australe as glycosidase inhibitors
por: Kato, A, et al.
Publicado: (2015)

Isolation and SAR studies of bicyclic iminosugars from Castanospermum australe as glycosidase inhibitors.
por: Kato, A, et al.
Publicado: (2015)

N- and C-alkylation of seven-membered iminosugars generates potent glucocerebrosidase inhibitors and F508del-CFTR correctors.
por: Désiré, J, et al.
Publicado: (2014)

Lucerastat, an iminosugar for substrate reduction therapy in Fabry disease: preclinical evidence
por: Priestman, D, et al.
Publicado: (2017)

The mechanism of action of iminosugars as antiretrovirals
por: Spiro, S, et al.
Publicado: (2014)